 Gene H. Kim
Concepts (707)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 61 | 2021 | 667 | 6.810 |
Why?
| | Heart Failure | 65 | 2021 | 1091 | 6.060 |
Why?
| | Ventricular Function, Left | 21 | 2020 | 586 | 2.340 |
Why?
| | Hemodynamics | 23 | 2020 | 710 | 2.310 |
Why?
| | Heart Ventricles | 19 | 2021 | 790 | 2.150 |
Why?
| | MicroRNAs | 7 | 2017 | 508 | 2.130 |
Why?
| | Heart Transplantation | 12 | 2021 | 661 | 1.670 |
Why?
| | Arrhythmias, Cardiac | 5 | 2017 | 208 | 1.570 |
Why?
| | Pulmonary Wedge Pressure | 12 | 2021 | 109 | 1.420 |
Why?
| | Middle Aged | 90 | 2021 | 25596 | 1.230 |
Why?
| | Aortic Valve Insufficiency | 7 | 2020 | 123 | 1.200 |
Why?
| | Myocardium | 6 | 2017 | 544 | 1.170 |
Why?
| | Humans | 144 | 2021 | 83447 | 1.160 |
Why?
| | Male | 105 | 2021 | 41899 | 1.100 |
Why?
| | Prosthesis Implantation | 7 | 2020 | 135 | 1.090 |
Why?
| | Cardiomyopathies | 6 | 2020 | 254 | 1.080 |
Why?
| | Female | 100 | 2021 | 44784 | 1.070 |
Why?
| | Skin Neoplasms | 6 | 2020 | 538 | 1.040 |
Why?
| | Cornea | 2 | 2014 | 97 | 1.020 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 88 | 0.990 |
Why?
| | Epigenesis, Genetic | 3 | 2017 | 434 | 0.950 |
Why?
| | Myocytes, Cardiac | 6 | 2016 | 249 | 0.940 |
Why?
| | Skin | 6 | 2020 | 560 | 0.900 |
Why?
| | Echocardiography | 16 | 2020 | 892 | 0.890 |
Why?
| | S100 Proteins | 5 | 2013 | 53 | 0.890 |
Why?
| | Gene Expression Regulation | 9 | 2017 | 1941 | 0.850 |
Why?
| | Folliculitis | 1 | 2020 | 2 | 0.840 |
Why?
| | Mesotherapy | 1 | 2020 | 2 | 0.840 |
Why?
| | Foot Diseases | 1 | 2019 | 13 | 0.830 |
Why?
| | Echocardiography, Doppler | 8 | 2020 | 197 | 0.810 |
Why?
| | Foot | 1 | 2019 | 54 | 0.810 |
Why?
| | Hemangioma | 1 | 2019 | 66 | 0.800 |
Why?
| | Gap Junctions | 2 | 2017 | 143 | 0.770 |
Why?
| | Signal Transduction | 9 | 2020 | 3301 | 0.760 |
Why?
| | Aged | 55 | 2021 | 18508 | 0.750 |
Why?
| | Immunoglobulin G | 4 | 2021 | 482 | 0.720 |
Why?
| | Cosmetic Techniques | 2 | 2015 | 38 | 0.710 |
Why?
| | Cardiology | 1 | 2019 | 123 | 0.700 |
Why?
| | Retrospective Studies | 33 | 2020 | 7644 | 0.690 |
Why?
| | Desmosomes | 1 | 2017 | 10 | 0.690 |
Why?
| | Disease Models, Animal | 9 | 2019 | 2299 | 0.690 |
Why?
| | Treatment Outcome | 34 | 2021 | 7905 | 0.690 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 13 | 0.690 |
Why?
| | Melanoma | 4 | 2020 | 507 | 0.680 |
Why?
| | Biopsy | 5 | 2019 | 1182 | 0.680 |
Why?
| | Leg Dermatoses | 1 | 2016 | 7 | 0.650 |
Why?
| | Heart Atria | 2 | 2019 | 248 | 0.650 |
Why?
| | Cryptococcosis | 1 | 2016 | 21 | 0.650 |
Why?
| | Intra-Aortic Balloon Pumping | 4 | 2020 | 70 | 0.650 |
Why?
| | Adult | 44 | 2021 | 25995 | 0.650 |
Why?
| | Cellulitis | 1 | 2016 | 22 | 0.650 |
Why?
| | Fungemia | 1 | 2016 | 24 | 0.640 |
Why?
| | Immunocompromised Host | 2 | 2020 | 144 | 0.640 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2016 | 34 | 0.640 |
Why?
| | Cardiovascular Diseases | 2 | 2014 | 815 | 0.630 |
Why?
| | Methanobrevibacter | 2 | 2013 | 3 | 0.630 |
Why?
| | Regeneration | 1 | 2017 | 154 | 0.620 |
Why?
| | Hemorrhage | 4 | 2018 | 248 | 0.620 |
Why?
| | Prospective Studies | 25 | 2021 | 4085 | 0.610 |
Why?
| | Acupuncture Therapy | 1 | 2015 | 10 | 0.600 |
Why?
| | Thrombosis | 5 | 2020 | 273 | 0.590 |
Why?
| | Sclerosis | 1 | 2015 | 30 | 0.590 |
Why?
| | Medical Oncology | 1 | 2019 | 332 | 0.590 |
Why?
| | Leg Ulcer | 1 | 2014 | 8 | 0.590 |
Why?
| | Cell Nucleus | 2 | 2017 | 589 | 0.580 |
Why?
| | Granuloma | 1 | 2015 | 52 | 0.580 |
Why?
| | Tetracaine | 1 | 2014 | 1 | 0.580 |
Why?
| | Irritable Bowel Syndrome | 2 | 2012 | 39 | 0.580 |
Why?
| | Eye Pain | 1 | 2014 | 5 | 0.580 |
Why?
| | Amnion | 1 | 2014 | 14 | 0.580 |
Why?
| | Coated Materials, Biocompatible | 1 | 2014 | 33 | 0.570 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2014 | 21 | 0.570 |
Why?
| | Immunosuppressive Agents | 3 | 2020 | 1026 | 0.570 |
Why?
| | Conjunctiva | 1 | 2014 | 24 | 0.570 |
Why?
| | Embolism | 1 | 2014 | 31 | 0.570 |
Why?
| | Eye Injuries | 1 | 2014 | 15 | 0.570 |
Why?
| | Heart Conduction System | 2 | 2012 | 154 | 0.570 |
Why?
| | Prostheses and Implants | 2 | 2018 | 152 | 0.560 |
Why?
| | Lasers, Excimer | 1 | 2014 | 6 | 0.560 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2014 | 4 | 0.560 |
Why?
| | Animals | 38 | 2020 | 26985 | 0.560 |
Why?
| | Photorefractive Keratectomy | 1 | 2014 | 6 | 0.560 |
Why?
| | Myopia | 1 | 2014 | 12 | 0.560 |
Why?
| | Face | 1 | 2015 | 129 | 0.550 |
Why?
| | Membrane Glycoproteins | 1 | 2017 | 433 | 0.550 |
Why?
| | Foreign Bodies | 1 | 2014 | 64 | 0.550 |
Why?
| | Trigeminal Nerve | 1 | 2013 | 18 | 0.540 |
Why?
| | Anesthetics, Local | 1 | 2014 | 80 | 0.540 |
Why?
| | Cardiomegaly | 6 | 2016 | 110 | 0.540 |
Why?
| | Prednisone | 3 | 2020 | 264 | 0.540 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 134 | 0.540 |
Why?
| | Suture Techniques | 1 | 2014 | 136 | 0.530 |
Why?
| | Connexin 43 | 1 | 2014 | 93 | 0.530 |
Why?
| | Nerve Fibers | 1 | 2013 | 44 | 0.520 |
Why?
| | Panniculitis | 1 | 2013 | 7 | 0.520 |
Why?
| | Thromboembolism | 3 | 2018 | 121 | 0.520 |
Why?
| | Lactoglobulins | 1 | 2012 | 7 | 0.510 |
Why?
| | Fox-Fordyce Disease | 1 | 2012 | 2 | 0.510 |
Why?
| | Xanthomatosis | 1 | 2012 | 10 | 0.510 |
Why?
| | Device Removal | 3 | 2020 | 163 | 0.510 |
Why?
| | Hypertrichosis | 1 | 2012 | 4 | 0.510 |
Why?
| | Neurocytoma | 1 | 2012 | 3 | 0.510 |
Why?
| | Cardiac Output | 5 | 2020 | 159 | 0.500 |
Why?
| | Facial Neoplasms | 1 | 2012 | 27 | 0.500 |
Why?
| | Heart | 4 | 2019 | 527 | 0.490 |
Why?
| | Methane | 1 | 2012 | 11 | 0.490 |
Why?
| | Follow-Up Studies | 15 | 2021 | 3877 | 0.490 |
Why?
| | Oxidation-Reduction | 1 | 2013 | 379 | 0.470 |
Why?
| | Mice | 24 | 2020 | 11133 | 0.470 |
Why?
| | Constipation | 1 | 2012 | 68 | 0.460 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2011 | 3 | 0.460 |
Why?
| | Facial Dermatoses | 1 | 2011 | 12 | 0.460 |
Why?
| | Mice, Transgenic | 13 | 2019 | 1553 | 0.460 |
Why?
| | Ultrasonography, Prenatal | 1 | 2013 | 177 | 0.460 |
Why?
| | Postoperative Complications | 9 | 2020 | 2263 | 0.450 |
Why?
| | Indoles | 1 | 2013 | 335 | 0.440 |
Why?
| | Sirtuin 3 | 4 | 2016 | 30 | 0.430 |
Why?
| | Sulfonamides | 1 | 2013 | 329 | 0.430 |
Why?
| | Hypertension, Pulmonary | 4 | 2020 | 341 | 0.430 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1605 | 0.420 |
Why?
| | Atrial Fibrillation | 4 | 2019 | 269 | 0.420 |
Why?
| | Lymphedema | 3 | 2020 | 69 | 0.420 |
Why?
| | Histiocytosis, Sinus | 2 | 2020 | 16 | 0.410 |
Why?
| | Recovery of Function | 4 | 2019 | 265 | 0.400 |
Why?
| | Kidney Transplantation | 3 | 2021 | 830 | 0.400 |
Why?
| | Aortic Valve | 4 | 2020 | 204 | 0.390 |
Why?
| | Echocardiography, Three-Dimensional | 4 | 2021 | 507 | 0.390 |
Why?
| | Tricuspid Valve | 2 | 2020 | 89 | 0.380 |
Why?
| | Methotrexate | 2 | 2020 | 262 | 0.380 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 233 | 0.380 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2009 | 90 | 0.380 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 348 | 0.380 |
Why?
| | Liver Transplantation | 4 | 2021 | 1249 | 0.380 |
Why?
| | Pulmonary Artery | 3 | 2021 | 298 | 0.380 |
Why?
| | Anti-Bacterial Agents | 3 | 2020 | 814 | 0.370 |
Why?
| | Counterpulsation | 2 | 2018 | 21 | 0.370 |
Why?
| | Tricuspid Valve Insufficiency | 2 | 2020 | 101 | 0.360 |
Why?
| | Cardiotonic Agents | 3 | 2019 | 82 | 0.360 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 120 | 0.360 |
Why?
| | Heart Valve Prosthesis Implantation | 2 | 2020 | 152 | 0.360 |
Why?
| | Pacemaker, Artificial | 2 | 2020 | 106 | 0.360 |
Why?
| | Coronary Artery Bypass | 3 | 2020 | 214 | 0.350 |
Why?
| | Lymph Node Excision | 2 | 2019 | 209 | 0.350 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2020 | 219 | 0.350 |
Why?
| | Radiotherapy | 2 | 2019 | 339 | 0.340 |
Why?
| | Photosensitivity Disorders | 1 | 2007 | 15 | 0.340 |
Why?
| | Lichen Planus | 1 | 2007 | 9 | 0.340 |
Why?
| | Protein Biosynthesis | 1 | 2009 | 379 | 0.330 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2013 | 247 | 0.320 |
Why?
| | Graft Rejection | 4 | 2021 | 1110 | 0.320 |
Why?
| | Energy Metabolism | 2 | 2019 | 265 | 0.320 |
Why?
| | Psoriasis | 1 | 2009 | 222 | 0.310 |
Why?
| | Wound Healing | 2 | 2020 | 348 | 0.310 |
Why?
| | Leiomyomatosis | 1 | 2005 | 13 | 0.310 |
Why?
| | Transcription Factors | 2 | 2014 | 1517 | 0.300 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 146 | 0.300 |
Why?
| | Nails, Malformed | 1 | 2004 | 4 | 0.290 |
Why?
| | Urticaria | 1 | 2004 | 11 | 0.290 |
Why?
| | Oxidative Stress | 4 | 2019 | 412 | 0.290 |
Why?
| | Time Factors | 12 | 2021 | 5496 | 0.290 |
Why?
| | Mitochondria | 3 | 2019 | 532 | 0.290 |
Why?
| | Hair | 1 | 2004 | 59 | 0.280 |
Why?
| | Craniofacial Abnormalities | 1 | 2004 | 37 | 0.280 |
Why?
| | Cold Temperature | 1 | 2004 | 161 | 0.280 |
Why?
| | Patient Readmission | 4 | 2020 | 276 | 0.270 |
Why?
| | DNA-Binding Proteins | 2 | 2012 | 1212 | 0.260 |
Why?
| | Osteopoikilosis | 1 | 2003 | 1 | 0.260 |
Why?
| | Skin Diseases, Genetic | 1 | 2003 | 2 | 0.260 |
Why?
| | Sirtuins | 3 | 2016 | 45 | 0.260 |
Why?
| | Central Venous Pressure | 2 | 2020 | 27 | 0.260 |
Why?
| | Visual Acuity | 2 | 2014 | 222 | 0.250 |
Why?
| | Anticoagulants | 4 | 2019 | 399 | 0.250 |
Why?
| | Uterine Neoplasms | 1 | 2005 | 184 | 0.250 |
Why?
| | Abnormalities, Multiple | 1 | 2004 | 250 | 0.250 |
Why?
| | T-Lymphocytes | 1 | 2009 | 1288 | 0.240 |
Why?
| | Complement C3d | 1 | 2021 | 6 | 0.240 |
Why?
| | 3' Untranslated Regions | 2 | 2014 | 90 | 0.240 |
Why?
| | Survival Rate | 7 | 2021 | 1919 | 0.230 |
Why?
| | NIH 3T3 Cells | 2 | 2014 | 107 | 0.230 |
Why?
| | Proportional Hazards Models | 6 | 2020 | 870 | 0.230 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2021 | 18 | 0.230 |
Why?
| | Aortic Aneurysm | 2 | 2014 | 80 | 0.230 |
Why?
| | Complement C4b | 1 | 2021 | 34 | 0.230 |
Why?
| | Blood Flow Velocity | 2 | 2019 | 207 | 0.230 |
Why?
| | Stroke Volume | 3 | 2019 | 436 | 0.230 |
Why?
| | Bone and Bones | 1 | 2003 | 268 | 0.230 |
Why?
| | Kidney Failure, Chronic | 2 | 2020 | 514 | 0.220 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2020 | 12 | 0.220 |
Why?
| | Glomus Tumor | 1 | 2020 | 6 | 0.220 |
Why?
| | Penicillin G Benzathine | 1 | 2020 | 5 | 0.220 |
Why?
| | Cohort Studies | 9 | 2020 | 2710 | 0.220 |
Why?
| | Apolipoproteins E | 2 | 2013 | 147 | 0.220 |
Why?
| | Atherosclerosis | 2 | 2014 | 234 | 0.220 |
Why?
| | Sulfadiazine | 1 | 2020 | 25 | 0.220 |
Why?
| | Risk Factors | 8 | 2020 | 5418 | 0.220 |
Why?
| | Treponema pallidum | 1 | 2020 | 9 | 0.220 |
Why?
| | Agammaglobulinemia | 1 | 2020 | 21 | 0.220 |
Why?
| | Trimethoprim | 1 | 2020 | 16 | 0.210 |
Why?
| | Epidermolysis Bullosa, Junctional | 1 | 2020 | 1 | 0.210 |
Why?
| | Ambulatory Care | 2 | 2018 | 178 | 0.210 |
Why?
| | Gentamicins | 1 | 2020 | 47 | 0.210 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 29 | 0.210 |
Why?
| | Cause of Death | 2 | 2018 | 273 | 0.210 |
Why?
| | Poroma | 1 | 2019 | 1 | 0.210 |
Why?
| | Syphilis | 1 | 2020 | 25 | 0.210 |
Why?
| | HIV Seropositivity | 1 | 2020 | 72 | 0.210 |
Why?
| | Codon, Nonsense | 1 | 2020 | 42 | 0.210 |
Why?
| | Mathematical Concepts | 1 | 2020 | 17 | 0.210 |
Why?
| | Sweat Gland Neoplasms | 1 | 2019 | 8 | 0.210 |
Why?
| | Risk Assessment | 5 | 2020 | 2284 | 0.200 |
Why?
| | Fontan Procedure | 1 | 2020 | 51 | 0.200 |
Why?
| | Porokeratosis | 1 | 2019 | 3 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2020 | 81 | 0.200 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 76 | 0.200 |
Why?
| | Electric Impedance | 1 | 2020 | 102 | 0.200 |
Why?
| | Vascular Stiffness | 1 | 2019 | 27 | 0.200 |
Why?
| | Hair Follicle | 1 | 2019 | 25 | 0.200 |
Why?
| | Syndrome | 3 | 2005 | 434 | 0.200 |
Why?
| | Intraoperative Care | 1 | 2020 | 94 | 0.200 |
Why?
| | Cheek | 2 | 2011 | 18 | 0.200 |
Why?
| | Cartilage | 2 | 2018 | 117 | 0.200 |
Why?
| | Protease Inhibitors | 1 | 2019 | 74 | 0.200 |
Why?
| | Vasodilation | 1 | 2019 | 99 | 0.200 |
Why?
| | Severity of Illness Index | 7 | 2020 | 1778 | 0.200 |
Why?
| | Tetrazoles | 1 | 2019 | 54 | 0.200 |
Why?
| | Sternotomy | 1 | 2019 | 17 | 0.200 |
Why?
| | Biphenyl Compounds | 2 | 2019 | 69 | 0.200 |
Why?
| | Myocarditis | 1 | 2019 | 46 | 0.200 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 166 | 0.200 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 164 | 0.200 |
Why?
| | Neoplasms, Second Primary | 2 | 2020 | 251 | 0.190 |
Why?
| | Peptide Fragments | 1 | 2021 | 480 | 0.190 |
Why?
| | Multiple Organ Failure | 1 | 2019 | 43 | 0.190 |
Why?
| | Remote Sensing Technology | 1 | 2018 | 5 | 0.190 |
Why?
| | Mice, Knockout | 8 | 2019 | 1953 | 0.190 |
Why?
| | Calcinosis | 2 | 2011 | 241 | 0.190 |
Why?
| | Assisted Circulation | 1 | 2018 | 14 | 0.190 |
Why?
| | Lunate Bone | 1 | 2018 | 2 | 0.190 |
Why?
| | Heart Function Tests | 1 | 2018 | 32 | 0.190 |
Why?
| | Shock, Cardiogenic | 1 | 2019 | 72 | 0.190 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 99 | 0.190 |
Why?
| | Guided Tissue Regeneration | 1 | 2018 | 7 | 0.190 |
Why?
| | Trapezium Bone | 1 | 2018 | 6 | 0.190 |
Why?
| | Thyroid Diseases | 1 | 2019 | 114 | 0.190 |
Why?
| | Donor Selection | 1 | 2019 | 66 | 0.190 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 250 | 0.190 |
Why?
| | Carpometacarpal Joints | 1 | 2018 | 12 | 0.190 |
Why?
| | Atrial Appendage | 1 | 2018 | 25 | 0.190 |
Why?
| | Subclavian Artery | 2 | 2015 | 38 | 0.190 |
Why?
| | Arthroplasty | 1 | 2018 | 29 | 0.190 |
Why?
| | Pemphigoid, Bullous | 2 | 2021 | 12 | 0.180 |
Why?
| | Alopecia | 2 | 2019 | 34 | 0.180 |
Why?
| | Reperfusion Injury | 1 | 2020 | 155 | 0.180 |
Why?
| | Mice, Inbred C57BL | 9 | 2019 | 3180 | 0.180 |
Why?
| | Enoxaparin | 1 | 2018 | 23 | 0.180 |
Why?
| | Octreotide | 1 | 2018 | 24 | 0.180 |
Why?
| | Tattooing | 1 | 2017 | 6 | 0.180 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2018 | 69 | 0.180 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 529 | 0.180 |
Why?
| | Erythema Nodosum | 1 | 2017 | 4 | 0.180 |
Why?
| | Graphite | 1 | 2017 | 9 | 0.180 |
Why?
| | Equipment Failure | 4 | 2020 | 123 | 0.180 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2018 | 56 | 0.180 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2018 | 55 | 0.180 |
Why?
| | Mitral Valve | 1 | 2020 | 233 | 0.180 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 17 | 0.180 |
Why?
| | Predictive Value of Tests | 6 | 2019 | 1758 | 0.180 |
Why?
| | Nevus, Pigmented | 1 | 2018 | 51 | 0.180 |
Why?
| | Heart Valve Diseases | 1 | 2018 | 101 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2019 | 76 | 0.180 |
Why?
| | Testosterone | 1 | 2019 | 285 | 0.180 |
Why?
| | Eye Injuries, Penetrating | 1 | 2017 | 9 | 0.180 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2018 | 167 | 0.180 |
Why?
| | Skin Ulcer | 1 | 2017 | 25 | 0.180 |
Why?
| | Rhinoplasty | 1 | 2018 | 31 | 0.180 |
Why?
| | Illusions | 1 | 2017 | 11 | 0.170 |
Why?
| | Thermodilution | 1 | 2017 | 21 | 0.170 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2018 | 108 | 0.170 |
Why?
| | Rats | 8 | 2020 | 4351 | 0.170 |
Why?
| | Desmocollins | 1 | 2017 | 3 | 0.170 |
Why?
| | Surgical Flaps | 1 | 2020 | 259 | 0.170 |
Why?
| | Secondary Prevention | 1 | 2018 | 164 | 0.170 |
Why?
| | Tachycardia, Ventricular | 1 | 2020 | 228 | 0.170 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 28 | 0.170 |
Why?
| | Atrial Flutter | 1 | 2017 | 46 | 0.170 |
Why?
| | Fibronectins | 1 | 2017 | 95 | 0.160 |
Why?
| | Insulin Resistance | 1 | 2019 | 388 | 0.160 |
Why?
| | Cryptococcus neoformans | 1 | 2016 | 15 | 0.160 |
Why?
| | Myocardial Ischemia | 2 | 2017 | 167 | 0.160 |
Why?
| | Fluconazole | 1 | 2016 | 16 | 0.160 |
Why?
| | Flucytosine | 1 | 2016 | 13 | 0.160 |
Why?
| | Catheter Ablation | 1 | 2020 | 348 | 0.160 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 44 | 0.160 |
Why?
| | Amphotericin B | 1 | 2016 | 46 | 0.160 |
Why?
| | Carbon Monoxide | 1 | 2017 | 92 | 0.160 |
Why?
| | Angiopoietin-2 | 1 | 2016 | 20 | 0.160 |
Why?
| | Prosthesis Design | 4 | 2019 | 303 | 0.160 |
Why?
| | Coloring Agents | 2 | 2012 | 71 | 0.160 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 281 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2017 | 161 | 0.160 |
Why?
| | Mitochondria, Heart | 1 | 2016 | 47 | 0.150 |
Why?
| | Superoxide Dismutase | 3 | 2015 | 186 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2017 | 230 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2018 | 2674 | 0.150 |
Why?
| | Lymph Nodes | 1 | 2020 | 532 | 0.150 |
Why?
| | Rats, Inbred SHR | 2 | 2017 | 29 | 0.150 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 122 | 0.150 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 291 | 0.150 |
Why?
| | Antifungal Agents | 1 | 2016 | 139 | 0.150 |
Why?
| | Lignans | 1 | 2015 | 6 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 164 | 0.150 |
Why?
| | Observer Variation | 2 | 2016 | 621 | 0.150 |
Why?
| | Lasers, Gas | 1 | 2014 | 4 | 0.150 |
Why?
| | Phenotype | 3 | 2017 | 2295 | 0.150 |
Why?
| | Cyclosporine | 1 | 2016 | 251 | 0.150 |
Why?
| | DNA, Mitochondrial | 1 | 2016 | 182 | 0.150 |
Why?
| | Doxorubicin | 1 | 2016 | 296 | 0.150 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2014 | 15 | 0.140 |
Why?
| | LIM Domain Proteins | 1 | 2014 | 25 | 0.140 |
Why?
| | Incidence | 5 | 2019 | 1639 | 0.140 |
Why?
| | Cephalosporins | 1 | 2014 | 42 | 0.140 |
Why?
| | Mesenteric Artery, Superior | 1 | 2014 | 21 | 0.140 |
Why?
| | Coronavirus Infections | 1 | 2020 | 284 | 0.140 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 310 | 0.140 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1682 | 0.140 |
Why?
| | Toxoplasmosis | 1 | 2015 | 65 | 0.140 |
Why?
| | Mitral Valve Insufficiency | 1 | 2016 | 175 | 0.140 |
Why?
| | Melkersson-Rosenthal Syndrome | 1 | 2014 | 1 | 0.140 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 2080 | 0.140 |
Why?
| | Refraction, Ocular | 1 | 2014 | 11 | 0.140 |
Why?
| | Posture | 1 | 2014 | 109 | 0.140 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 434 | 0.140 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2014 | 11 | 0.140 |
Why?
| | Eyelid Diseases | 1 | 2014 | 8 | 0.140 |
Why?
| | Nails | 1 | 2014 | 8 | 0.140 |
Why?
| | Transduction, Genetic | 1 | 2014 | 153 | 0.140 |
Why?
| | Luciferases | 1 | 2014 | 122 | 0.140 |
Why?
| | Infant | 3 | 2021 | 3103 | 0.140 |
Why?
| | Transforming Growth Factor beta | 2 | 2013 | 286 | 0.140 |
Why?
| | Exosomes | 1 | 2014 | 49 | 0.140 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 89 | 0.140 |
Why?
| | Immunohistochemistry | 4 | 2021 | 1823 | 0.140 |
Why?
| | Connective Tissue Diseases | 1 | 2014 | 70 | 0.140 |
Why?
| | Catheterization, Peripheral | 1 | 2014 | 65 | 0.140 |
Why?
| | Mutation, Missense | 2 | 2013 | 276 | 0.130 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 103 | 0.130 |
Why?
| | Frozen Sections | 1 | 2014 | 47 | 0.130 |
Why?
| | Hospitalization | 1 | 2019 | 767 | 0.130 |
Why?
| | Patient Positioning | 1 | 2014 | 67 | 0.130 |
Why?
| | Vasculitis | 2 | 2013 | 40 | 0.130 |
Why?
| | Edema | 1 | 2014 | 74 | 0.130 |
Why?
| | DNA Damage | 1 | 2016 | 357 | 0.130 |
Why?
| | Genetic Testing | 1 | 2018 | 502 | 0.130 |
Why?
| | Neovascularization, Pathologic | 1 | 2016 | 356 | 0.130 |
Why?
| | Gastrointestinal Agents | 2 | 2018 | 177 | 0.130 |
Why?
| | Genes, Reporter | 1 | 2014 | 268 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2020 | 2969 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 1047 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 1036 | 0.130 |
Why?
| | Carmine | 1 | 2012 | 1 | 0.130 |
Why?
| | Foam Cells | 1 | 2012 | 17 | 0.130 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 8 | 0.130 |
Why?
| | Oxygen Consumption | 1 | 2014 | 250 | 0.130 |
Why?
| | Prognosis | 5 | 2021 | 3709 | 0.130 |
Why?
| | Illinois | 3 | 2019 | 467 | 0.130 |
Why?
| | Electrocardiography | 4 | 2019 | 583 | 0.130 |
Why?
| | Oncogene Protein v-akt | 1 | 2012 | 22 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2569 | 0.130 |
Why?
| | Mucins | 1 | 2012 | 44 | 0.130 |
Why?
| | Reoperation | 3 | 2020 | 623 | 0.130 |
Why?
| | Plaque, Atherosclerotic | 1 | 2013 | 41 | 0.130 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2012 | 53 | 0.120 |
Why?
| | Genetic Vectors | 1 | 2014 | 449 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 296 | 0.120 |
Why?
| | Electrophysiological Phenomena | 1 | 2012 | 52 | 0.120 |
Why?
| | Acute Disease | 1 | 2014 | 862 | 0.120 |
Why?
| | Lung | 1 | 2018 | 1061 | 0.120 |
Why?
| | Breath Tests | 1 | 2012 | 54 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 303 | 0.120 |
Why?
| | Axilla | 1 | 2012 | 97 | 0.120 |
Why?
| | Models, Cardiovascular | 1 | 2012 | 102 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 757 | 0.120 |
Why?
| | Quinolines | 1 | 2013 | 98 | 0.120 |
Why?
| | Physicians | 1 | 2019 | 609 | 0.120 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 116 | 0.120 |
Why?
| | Staining and Labeling | 1 | 2012 | 187 | 0.120 |
Why?
| | Hydrogen | 1 | 2012 | 55 | 0.120 |
Why?
| | Weight Gain | 1 | 2013 | 138 | 0.120 |
Why?
| | Collagen Type VII | 1 | 2011 | 3 | 0.120 |
Why?
| | Epidermolysis Bullosa Acquisita | 1 | 2011 | 2 | 0.120 |
Why?
| | Calcium Signaling | 1 | 2012 | 132 | 0.120 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 571 | 0.120 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 568 | 0.120 |
Why?
| | Cell Communication | 1 | 2012 | 190 | 0.120 |
Why?
| | Dermatologic Agents | 1 | 2012 | 69 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 137 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2018 | 759 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 4 | 2020 | 1370 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 359 | 0.120 |
Why?
| | Rifamycins | 1 | 2011 | 5 | 0.110 |
Why?
| | RNA, Bacterial | 1 | 2012 | 112 | 0.110 |
Why?
| | Sodium Channels | 1 | 2012 | 130 | 0.110 |
Why?
| | Environment | 1 | 2013 | 219 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2016 | 372 | 0.110 |
Why?
| | T-Box Domain Proteins | 1 | 2012 | 100 | 0.110 |
Why?
| | Homeostasis | 1 | 2013 | 397 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2012 | 250 | 0.110 |
Why?
| | DNA, Bacterial | 1 | 2012 | 271 | 0.110 |
Why?
| | Muscle, Skeletal | 1 | 2014 | 451 | 0.110 |
Why?
| | Disease Progression | 3 | 2020 | 1474 | 0.110 |
Why?
| | Ion Channels | 1 | 2012 | 260 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 3 | 2018 | 898 | 0.110 |
Why?
| | Histones | 1 | 2013 | 308 | 0.110 |
Why?
| | Muscle Contraction | 3 | 2019 | 306 | 0.110 |
Why?
| | Intestine, Small | 1 | 2013 | 343 | 0.110 |
Why?
| | Mitochondria, Muscle | 1 | 2010 | 28 | 0.110 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2010 | 14 | 0.110 |
Why?
| | Ergocalciferols | 1 | 2010 | 39 | 0.110 |
Why?
| | Child | 3 | 2021 | 6768 | 0.100 |
Why?
| | Autoimmunity | 1 | 2011 | 163 | 0.100 |
Why?
| | Fibroblasts | 4 | 2016 | 731 | 0.100 |
Why?
| | Recurrence | 3 | 2018 | 1196 | 0.100 |
Why?
| | Neural Crest | 1 | 2010 | 25 | 0.100 |
Why?
| | Child, Preschool | 3 | 2020 | 3758 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2011 | 117 | 0.100 |
Why?
| | NAD | 1 | 2009 | 74 | 0.100 |
Why?
| | Feces | 1 | 2012 | 356 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2010 | 74 | 0.100 |
Why?
| | Rare Diseases | 2 | 2020 | 60 | 0.100 |
Why?
| | Lymphatic System | 2 | 2019 | 51 | 0.100 |
Why?
| | Drug Combinations | 2 | 2020 | 245 | 0.100 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 62 | 0.100 |
Why?
| | Biopsy, Needle | 2 | 2020 | 268 | 0.100 |
Why?
| | Mice, Inbred Strains | 1 | 2009 | 331 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6577 | 0.090 |
Why?
| | Osteogenesis | 1 | 2010 | 241 | 0.090 |
Why?
| | Forkhead Transcription Factors | 1 | 2009 | 155 | 0.090 |
Why?
| | Mitochondrial Proteins | 1 | 2009 | 118 | 0.090 |
Why?
| | Delayed-Action Preparations | 2 | 2019 | 155 | 0.090 |
Why?
| | DNA Methylation | 1 | 2013 | 577 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2015 | 1613 | 0.090 |
Why?
| | Tissue Donors | 2 | 2021 | 435 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2362 | 0.090 |
Why?
| | Vitamin D | 1 | 2010 | 264 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2015 | 1474 | 0.090 |
Why?
| | Hydroquinones | 1 | 2007 | 9 | 0.090 |
Why?
| | Young Adult | 4 | 2021 | 5970 | 0.080 |
Why?
| | Blood Pressure | 1 | 2013 | 1200 | 0.080 |
Why?
| | Hair Removal | 1 | 2007 | 13 | 0.080 |
Why?
| | Forehead | 1 | 2007 | 18 | 0.080 |
Why?
| | Exercise Test | 2 | 2019 | 175 | 0.080 |
Why?
| | Reactive Oxygen Species | 3 | 2016 | 459 | 0.080 |
Why?
| | Radiation-Protective Agents | 1 | 2007 | 101 | 0.080 |
Why?
| | United States | 4 | 2021 | 6316 | 0.080 |
Why?
| | Fumarate Hydratase | 1 | 2005 | 6 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 940 | 0.080 |
Why?
| | Cell Movement | 1 | 2010 | 745 | 0.080 |
Why?
| | Reference Values | 2 | 2018 | 702 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 937 | 0.080 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 194 | 0.080 |
Why?
| | Alopecia Areata | 1 | 2005 | 4 | 0.080 |
Why?
| | Pregnancy | 1 | 2013 | 2818 | 0.080 |
Why?
| | Academic Medical Centers | 2 | 2018 | 393 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2005 | 84 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2007 | 302 | 0.070 |
Why?
| | Survival Analysis | 2 | 2020 | 1584 | 0.070 |
Why?
| | Patient Selection | 2 | 2020 | 698 | 0.070 |
Why?
| | Point Mutation | 1 | 2005 | 266 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2009 | 697 | 0.070 |
Why?
| | Acetylcholine | 1 | 2004 | 186 | 0.070 |
Why?
| | Ultrasonography | 2 | 2020 | 696 | 0.070 |
Why?
| | Random Allocation | 2 | 2018 | 376 | 0.070 |
Why?
| | Dacryocystorhinostomy | 1 | 2004 | 4 | 0.070 |
Why?
| | Acetylation | 2 | 2015 | 121 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 343 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 303 | 0.070 |
Why?
| | Collagen | 2 | 2019 | 277 | 0.070 |
Why?
| | Elastic Tissue | 2 | 2014 | 17 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2014 | 233 | 0.060 |
Why?
| | Age Factors | 2 | 2018 | 1916 | 0.060 |
Why?
| | Dermatitis Herpetiformis | 1 | 2021 | 9 | 0.060 |
Why?
| | Pemphigus | 1 | 2021 | 16 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2021 | 77 | 0.060 |
Why?
| | Animals, Newborn | 2 | 2014 | 562 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2013 | 1996 | 0.060 |
Why?
| | ABO Blood-Group System | 1 | 2021 | 66 | 0.060 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2021 | 23 | 0.060 |
Why?
| | Immunoglobulin M | 1 | 2021 | 172 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2013 | 132 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 694 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2021 | 98 | 0.060 |
Why?
| | Bilirubin | 1 | 2021 | 129 | 0.060 |
Why?
| | Axillary Artery | 1 | 2020 | 13 | 0.050 |
Why?
| | Trauma Severity Indices | 1 | 2020 | 39 | 0.050 |
Why?
| | Pilot Projects | 2 | 2019 | 836 | 0.050 |
Why?
| | Syphilis Serodiagnosis | 1 | 2020 | 4 | 0.050 |
Why?
| | Aorta | 2 | 2013 | 298 | 0.050 |
Why?
| | Radiography | 1 | 2003 | 873 | 0.050 |
Why?
| | Syphilis, Cutaneous | 1 | 2020 | 4 | 0.050 |
Why?
| | Immunocompetence | 1 | 2020 | 27 | 0.050 |
Why?
| | Mice, Inbred ICR | 1 | 2020 | 70 | 0.050 |
Why?
| | California | 1 | 2020 | 135 | 0.050 |
Why?
| | Thoracic Surgical Procedures | 1 | 2020 | 41 | 0.050 |
Why?
| | Exanthema | 1 | 2020 | 32 | 0.050 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 164 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2020 | 52 | 0.050 |
Why?
| | Hyponatremia | 1 | 2020 | 25 | 0.050 |
Why?
| | Rats, Transgenic | 1 | 2019 | 3 | 0.050 |
Why?
| | Epigastric Arteries | 1 | 2020 | 11 | 0.050 |
Why?
| | Euthyroid Sick Syndromes | 1 | 2019 | 10 | 0.050 |
Why?
| | Reperfusion | 1 | 2020 | 30 | 0.050 |
Why?
| | Succinate Dehydrogenase | 1 | 2019 | 15 | 0.050 |
Why?
| | Sturge-Weber Syndrome | 1 | 2019 | 6 | 0.050 |
Why?
| | Dissection | 1 | 2020 | 47 | 0.050 |
Why?
| | Neprilysin | 1 | 2019 | 40 | 0.050 |
Why?
| | Neurotransmitter Agents | 1 | 2020 | 112 | 0.050 |
Why?
| | Endocrine System Diseases | 1 | 2019 | 30 | 0.050 |
Why?
| | Electron Transport Complex IV | 1 | 2019 | 47 | 0.050 |
Why?
| | Femoral Artery | 1 | 2020 | 89 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2020 | 82 | 0.050 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2019 | 32 | 0.050 |
Why?
| | Hyperthyroidism | 1 | 2019 | 69 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2020 | 308 | 0.050 |
Why?
| | Materials Testing | 1 | 2019 | 101 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2021 | 222 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 127 | 0.050 |
Why?
| | Hindlimb | 1 | 2019 | 88 | 0.050 |
Why?
| | Hyperplasia | 1 | 2019 | 157 | 0.050 |
Why?
| | Metabolic Diseases | 1 | 2019 | 54 | 0.050 |
Why?
| | Neck | 1 | 2019 | 94 | 0.050 |
Why?
| | Keratinocytes | 1 | 2020 | 134 | 0.050 |
Why?
| | Epidermis | 1 | 2019 | 98 | 0.050 |
Why?
| | Heparin | 1 | 2019 | 185 | 0.050 |
Why?
| | Head | 1 | 2019 | 125 | 0.050 |
Why?
| | Systole | 1 | 2019 | 142 | 0.050 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 125 | 0.050 |
Why?
| | Thyrotropin | 1 | 2019 | 269 | 0.050 |
Why?
| | Organ Size | 1 | 2019 | 381 | 0.050 |
Why?
| | Administration, Oral | 1 | 2020 | 726 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 1021 | 0.050 |
Why?
| | Rats, Nude | 1 | 2018 | 23 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 322 | 0.050 |
Why?
| | Injections, Intramuscular | 1 | 2018 | 66 | 0.050 |
Why?
| | Ink | 1 | 2017 | 4 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2019 | 207 | 0.050 |
Why?
| | Patient Compliance | 1 | 2020 | 248 | 0.050 |
Why?
| | Thyroxine | 1 | 2019 | 322 | 0.050 |
Why?
| | International Normalized Ratio | 1 | 2018 | 41 | 0.040 |
Why?
| | Fascia | 1 | 2018 | 30 | 0.040 |
Why?
| | Medical History Taking | 1 | 2018 | 83 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2018 | 139 | 0.040 |
Why?
| | Mutation | 1 | 2009 | 3862 | 0.040 |
Why?
| | Hospitals, University | 1 | 2018 | 202 | 0.040 |
Why?
| | Ischemia | 1 | 2020 | 248 | 0.040 |
Why?
| | Graft Survival | 1 | 2021 | 884 | 0.040 |
Why?
| | Registries | 1 | 2021 | 662 | 0.040 |
Why?
| | Neutropenia | 1 | 2018 | 223 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 789 | 0.040 |
Why?
| | Administration, Topical | 1 | 2017 | 98 | 0.040 |
Why?
| | Hypoalbuminemia | 1 | 2017 | 7 | 0.040 |
Why?
| | Protein Array Analysis | 1 | 2017 | 52 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2001 | 319 | 0.040 |
Why?
| | Rats, Inbred WKY | 1 | 2017 | 31 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2021 | 988 | 0.040 |
Why?
| | Rabbits | 1 | 2018 | 716 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 1012 | 0.040 |
Why?
| | Tachycardia | 1 | 2017 | 47 | 0.040 |
Why?
| | Protein Binding | 2 | 2013 | 1509 | 0.040 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2017 | 39 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 991 | 0.040 |
Why?
| | Cystathionine gamma-Lyase | 1 | 2017 | 35 | 0.040 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2018 | 116 | 0.040 |
Why?
| | Epithelium | 1 | 2018 | 321 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2019 | 323 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2018 | 331 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 375 | 0.040 |
Why?
| | Equipment Safety | 1 | 2016 | 32 | 0.040 |
Why?
| | Thrombin | 1 | 2016 | 59 | 0.040 |
Why?
| | Risk | 1 | 2018 | 700 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 61 | 0.040 |
Why?
| | DNA Adducts | 1 | 2016 | 19 | 0.040 |
Why?
| | Arteriovenous Malformations | 1 | 2016 | 42 | 0.040 |
Why?
| | Swine | 1 | 2018 | 570 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2017 | 113 | 0.040 |
Why?
| | DNA Glycosylases | 1 | 2016 | 21 | 0.040 |
Why?
| | Deoxyguanosine | 1 | 2016 | 29 | 0.040 |
Why?
| | Prevalence | 1 | 2020 | 1264 | 0.040 |
Why?
| | Length of Stay | 1 | 2019 | 697 | 0.040 |
Why?
| | Hydrolysis | 1 | 2016 | 154 | 0.040 |
Why?
| | Atovaquone | 1 | 2015 | 4 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2018 | 189 | 0.040 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2015 | 5 | 0.040 |
Why?
| | Phenylephrine | 1 | 2015 | 40 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2015 | 50 | 0.040 |
Why?
| | Adolescent | 2 | 2020 | 9140 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2001 | 634 | 0.040 |
Why?
| | Isoproterenol | 1 | 2015 | 68 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 295 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2016 | 147 | 0.040 |
Why?
| | Respiration | 1 | 2017 | 243 | 0.040 |
Why?
| | Neuromuscular Junction Diseases | 1 | 2014 | 3 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2015 | 78 | 0.040 |
Why?
| | Contrast Media | 1 | 2020 | 1083 | 0.040 |
Why?
| | Equipment Design | 1 | 2016 | 422 | 0.040 |
Why?
| | Sex Factors | 1 | 2018 | 1090 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2015 | 38 | 0.040 |
Why?
| | Cell Death | 1 | 2016 | 273 | 0.040 |
Why?
| | Pandemics | 1 | 2020 | 538 | 0.040 |
Why?
| | Lung Diseases | 1 | 2017 | 268 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 1825 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 1452 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 106 | 0.040 |
Why?
| | Radiography, Abdominal | 1 | 2014 | 65 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1011 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 1196 | 0.030 |
Why?
| | KATP Channels | 1 | 2014 | 19 | 0.030 |
Why?
| | Ultrasonography, Doppler | 1 | 2014 | 69 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 32 | 0.030 |
Why?
| | Adenosine Triphosphatases | 1 | 2015 | 154 | 0.030 |
Why?
| | Carotid Body | 1 | 2017 | 223 | 0.030 |
Why?
| | Aortography | 1 | 2013 | 63 | 0.030 |
Why?
| | rho GTP-Binding Proteins | 1 | 2013 | 54 | 0.030 |
Why?
| | Calgranulin B | 1 | 2013 | 12 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2015 | 737 | 0.030 |
Why?
| | Fatty Acids | 1 | 2014 | 146 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2016 | 402 | 0.030 |
Why?
| | Tetrazolium Salts | 1 | 2012 | 12 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2100 | 0.030 |
Why?
| | Hypotension | 1 | 2013 | 74 | 0.030 |
Why?
| | NFATC Transcription Factors | 1 | 2012 | 28 | 0.030 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2013 | 86 | 0.030 |
Why?
| | Leucine | 1 | 2012 | 69 | 0.030 |
Why?
| | Body Weight | 1 | 2014 | 503 | 0.030 |
Why?
| | Histone Demethylases | 1 | 2012 | 25 | 0.030 |
Why?
| | Stroke | 1 | 2020 | 792 | 0.030 |
Why?
| | Zinc | 1 | 2013 | 95 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 75 | 0.030 |
Why?
| | Quality of Life | 1 | 2020 | 1369 | 0.030 |
Why?
| | Immunoglobulin E | 1 | 2012 | 143 | 0.030 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 1007 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2013 | 105 | 0.030 |
Why?
| | Thiazoles | 1 | 2012 | 130 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 119 | 0.030 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 173 | 0.030 |
Why?
| | Fibrosis | 1 | 2012 | 191 | 0.030 |
Why?
| | Eosinophils | 1 | 2012 | 192 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 672 | 0.030 |
Why?
| | Heart Diseases | 1 | 2014 | 314 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 409 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 286 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 1434 | 0.030 |
Why?
| | Retreatment | 1 | 2011 | 106 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2015 | 685 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2012 | 247 | 0.030 |
Why?
| | Body Mass Index | 1 | 2014 | 784 | 0.030 |
Why?
| | Rats, Mutant Strains | 1 | 2010 | 27 | 0.030 |
Why?
| | Connexins | 1 | 2012 | 195 | 0.030 |
Why?
| | SOXD Transcription Factors | 1 | 2010 | 1 | 0.030 |
Why?
| | Up-Regulation | 1 | 2013 | 712 | 0.030 |
Why?
| | Biomimetics | 1 | 2010 | 25 | 0.030 |
Why?
| | African Americans | 1 | 2019 | 1167 | 0.030 |
Why?
| | Butadienes | 1 | 2010 | 33 | 0.030 |
Why?
| | SOX9 Transcription Factor | 1 | 2010 | 22 | 0.030 |
Why?
| | Losartan | 1 | 2010 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1064 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2010 | 103 | 0.030 |
Why?
| | Cell Membrane | 1 | 2014 | 700 | 0.030 |
Why?
| | Renin | 1 | 2010 | 76 | 0.030 |
Why?
| | Aggrecans | 1 | 2010 | 47 | 0.030 |
Why?
| | Chondrocytes | 1 | 2010 | 61 | 0.030 |
Why?
| | Hypertrophy | 1 | 2009 | 65 | 0.030 |
Why?
| | Heterochromatin | 1 | 2009 | 23 | 0.030 |
Why?
| | Nuclear Envelope | 1 | 2009 | 38 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2012 | 268 | 0.030 |
Why?
| | Vitamins | 1 | 2010 | 74 | 0.030 |
Why?
| | Chromatin | 1 | 2012 | 344 | 0.030 |
Why?
| | Nitriles | 1 | 2010 | 141 | 0.030 |
Why?
| | Stress Fibers | 1 | 2009 | 24 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2010 | 252 | 0.030 |
Why?
| | Catalase | 1 | 2009 | 57 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 2010 | 165 | 0.030 |
Why?
| | Diet | 1 | 2013 | 451 | 0.030 |
Why?
| | Laminin | 1 | 2009 | 86 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 324 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 338 | 0.020 |
Why?
| | Binding Sites | 1 | 2012 | 1122 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2019 | 1480 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 942 | 0.020 |
Why?
| | Adenoviridae | 1 | 2010 | 348 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1331 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2009 | 237 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2009 | 230 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 571 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 831 | 0.020 |
Why?
| | Antioxidants | 1 | 2009 | 231 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1207 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 924 | 0.020 |
Why?
| | Indiana | 1 | 2006 | 11 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2010 | 674 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 574 | 0.020 |
Why?
| | Base Sequence | 1 | 2009 | 2430 | 0.020 |
Why?
| | Skin Diseases | 1 | 2006 | 163 | 0.020 |
Why?
| | Surgical Instruments | 1 | 2004 | 63 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2006 | 265 | 0.020 |
Why?
| | Apoptosis | 1 | 2010 | 1775 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 397 | 0.010 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 590 | 0.010 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|